CA2856034C - Cyclosporin a form 2 and method of making same - Google Patents
Cyclosporin a form 2 and method of making same Download PDFInfo
- Publication number
- CA2856034C CA2856034C CA2856034A CA2856034A CA2856034C CA 2856034 C CA2856034 C CA 2856034C CA 2856034 A CA2856034 A CA 2856034A CA 2856034 A CA2856034 A CA 2856034A CA 2856034 C CA2856034 C CA 2856034C
- Authority
- CA
- Canada
- Prior art keywords
- suspension
- hours
- temperature
- heating
- cyclosporin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 91
- 238000004519 manufacturing process Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 44
- 108010036949 Cyclosporine Proteins 0.000 claims description 40
- 229930105110 Cyclosporin A Natural products 0.000 claims description 38
- 239000000725 suspension Substances 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- 229960001265 ciclosporin Drugs 0.000 claims description 35
- 238000001816 cooling Methods 0.000 claims description 30
- 238000010438 heat treatment Methods 0.000 claims description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 17
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 229940068968 polysorbate 80 Drugs 0.000 claims description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 6
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 56
- 239000013078 crystal Substances 0.000 description 14
- 239000007858 starting material Substances 0.000 description 12
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 10
- 210000000795 conjunctiva Anatomy 0.000 description 9
- 208000002205 allergic conjunctivitis Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000004175 meibomian gland Anatomy 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 6
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 6
- 206010013774 Dry eye Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 208000024998 atopic conjunctivitis Diseases 0.000 description 5
- 208000010217 blepharitis Diseases 0.000 description 5
- 206010027137 Meibomianitis Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 239000004973 liquid crystal related substance Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 3
- 206010069664 atopic keratoconjunctivitis Diseases 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 229940053174 restasis Drugs 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000004489 tear production Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002336 sorption--desorption measurement Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 206010061842 Entropion Diseases 0.000 description 1
- 206010015993 Eyelid oedema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000014260 Fungal keratitis Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010037508 Punctate keratitis Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010044604 Trichiasis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000001891 corneal deposit Diseases 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003112 degranulating effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- KVIPHDKUOLVVQN-UHFFFAOYSA-N ethene;hydrate Chemical group O.C=C KVIPHDKUOLVVQN-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 206010023365 keratopathy Diseases 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 201000003827 punctate epithelial keratoconjunctivitis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000024205 superior limbic keratoconjunctivitis Diseases 0.000 description 1
- 230000004488 tear evaporation Effects 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
- C07K1/306—Extraction; Separation; Purification by precipitation by crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161559830P | 2011-11-15 | 2011-11-15 | |
| US61/559,830 | 2011-11-15 | ||
| PCT/US2012/064985 WO2013074608A1 (en) | 2011-11-15 | 2012-11-14 | Cyclosporine a form 2 and method of making same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2856034A1 CA2856034A1 (en) | 2013-05-23 |
| CA2856034C true CA2856034C (en) | 2017-12-12 |
Family
ID=47222337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2856034A Active CA2856034C (en) | 2011-11-15 | 2012-11-14 | Cyclosporin a form 2 and method of making same |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US8796221B2 (enExample) |
| EP (2) | EP2780358B1 (enExample) |
| JP (2) | JP6204921B2 (enExample) |
| KR (1) | KR102072252B1 (enExample) |
| CN (1) | CN104039813B (enExample) |
| AU (3) | AU2012339693B2 (enExample) |
| BR (1) | BR112014011768A2 (enExample) |
| CA (1) | CA2856034C (enExample) |
| ES (2) | ES2578154T3 (enExample) |
| RU (1) | RU2635547C2 (enExample) |
| WO (1) | WO2013074608A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014011768A2 (pt) * | 2011-11-15 | 2017-05-09 | Allergan Inc | forma 2 de ciclosporina a e método de produção da mesma |
| AU2013267435B2 (en) | 2012-06-01 | 2017-11-09 | Allergan, Inc. | Cyclosporin A analogs |
| US10780048B2 (en) | 2014-07-18 | 2020-09-22 | Allergan, Inc. | Suspension compositions of cyclosporin A for subconjunctival and periocular injection |
| TW201639873A (zh) | 2015-01-08 | 2016-11-16 | 歐樂根公司 | Ｍｅｂｍｔ側鏈已環化之環孢菌素衍生物 |
| CN113117359B (zh) * | 2021-03-05 | 2022-08-26 | 湘雅生物医药(湖州)有限公司 | 一种用于胶原蛋白提取用的无菌式蒸馏瓶 |
| EP4585605A1 (en) | 2022-10-20 | 2025-07-16 | Chugai Seiyaku Kabushiki Kaisha | Method for producing cyclic peptide crystals |
| TW202502802A (zh) | 2023-03-20 | 2025-01-16 | 日商中外製藥股份有限公司 | 環狀胜肽共晶體的製造方法 |
| CN116879437A (zh) * | 2023-07-11 | 2023-10-13 | 苏州欧康维视生物科技有限公司 | 一种检测眼用植入剂的体外释放的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0391909B1 (en) | 1987-09-03 | 1994-08-17 | The University Of Georgia Research Foundation, Inc. | Ocular cyclosporin composition |
| HU203564B (en) | 1987-12-21 | 1991-08-28 | Sandoz Ag | Process for producing new orthorombos cyclosporin without solvatation |
| GB8916901D0 (en) * | 1989-07-24 | 1989-09-06 | Sandoz Ltd | Improvements in or relating to organic compounds |
| GB9105705D0 (en) * | 1991-03-18 | 1991-05-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US5382714A (en) * | 1994-03-17 | 1995-01-17 | The Catholic University Of America | Process for isolation, purification, and recrystallization of lutein from saponified marigold oleoresin and uses thereof |
| ES2177652T3 (es) * | 1994-11-03 | 2002-12-16 | Novartis Ag | Nuevas formas de preparacion de ciclosporina para la aplicacion oral con composicion simple y alta biodisponibilidad, y procedimiento para su obtencion. |
| TW581681B (en) * | 1998-02-20 | 2004-04-01 | Nektar Therapeutics | Liquid crystal forms of cyclosporin |
| JP4208281B2 (ja) * | 1998-02-26 | 2009-01-14 | キヤノン株式会社 | 積層型光起電力素子 |
| US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
| DE602005011928D1 (de) | 2004-01-20 | 2009-02-05 | Allergan Inc | Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure |
| US10137083B2 (en) | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
| EP3521302A1 (en) * | 2011-05-27 | 2019-08-07 | Allergan, Inc. | A new crystalline form of cyclosporine a, methods of preparation, and methods for use thereof |
| BR112014011768A2 (pt) * | 2011-11-15 | 2017-05-09 | Allergan Inc | forma 2 de ciclosporina a e método de produção da mesma |
-
2012
- 2012-11-14 BR BR112014011768A patent/BR112014011768A2/pt not_active Application Discontinuation
- 2012-11-14 JP JP2014542396A patent/JP6204921B2/ja not_active Expired - Fee Related
- 2012-11-14 WO PCT/US2012/064985 patent/WO2013074608A1/en not_active Ceased
- 2012-11-14 CA CA2856034A patent/CA2856034C/en active Active
- 2012-11-14 AU AU2012339693A patent/AU2012339693B2/en not_active Ceased
- 2012-11-14 RU RU2014123468A patent/RU2635547C2/ru active
- 2012-11-14 KR KR1020147016151A patent/KR102072252B1/ko not_active Expired - Fee Related
- 2012-11-14 EP EP12791059.4A patent/EP2780358B1/en active Active
- 2012-11-14 ES ES12791059.4T patent/ES2578154T3/es active Active
- 2012-11-14 US US13/676,339 patent/US8796221B2/en active Active
- 2012-11-14 EP EP16156092.5A patent/EP3067363B1/en active Active
- 2012-11-14 CN CN201280066581.8A patent/CN104039813B/zh not_active Expired - Fee Related
- 2012-11-14 ES ES16156092.5T patent/ES2666191T3/es active Active
-
2014
- 2014-06-19 US US14/309,547 patent/US9352014B2/en active Active
-
2016
- 2016-05-26 US US15/165,997 patent/US10017541B2/en active Active
-
2017
- 2017-09-01 JP JP2017168227A patent/JP6513755B2/ja active Active
- 2017-12-06 AU AU2017272197A patent/AU2017272197A1/en not_active Abandoned
-
2018
- 2018-07-06 US US16/028,956 patent/US20180312543A1/en not_active Abandoned
-
2019
- 2019-06-28 AU AU2019204591A patent/AU2019204591B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019204591B2 (en) | 2021-03-25 |
| EP3067363B1 (en) | 2018-01-17 |
| KR102072252B1 (ko) | 2020-01-31 |
| US10017541B2 (en) | 2018-07-10 |
| ES2578154T3 (es) | 2016-07-21 |
| AU2012339693B2 (en) | 2017-09-07 |
| EP2780358B1 (en) | 2016-03-23 |
| US9352014B2 (en) | 2016-05-31 |
| WO2013074608A1 (en) | 2013-05-23 |
| JP2017210488A (ja) | 2017-11-30 |
| RU2014123468A (ru) | 2015-12-27 |
| JP6513755B2 (ja) | 2019-05-15 |
| US20140303343A1 (en) | 2014-10-09 |
| BR112014011768A2 (pt) | 2017-05-09 |
| JP2014533300A (ja) | 2014-12-11 |
| CN104039813B (zh) | 2017-08-29 |
| EP3067363A1 (en) | 2016-09-14 |
| AU2012339693A1 (en) | 2014-06-05 |
| US20160272681A1 (en) | 2016-09-22 |
| EP2780358A1 (en) | 2014-09-24 |
| ES2666191T3 (es) | 2018-05-03 |
| AU2017272197A1 (en) | 2018-01-04 |
| US20180312543A1 (en) | 2018-11-01 |
| US8796221B2 (en) | 2014-08-05 |
| CA2856034A1 (en) | 2013-05-23 |
| JP6204921B2 (ja) | 2017-09-27 |
| KR20140101790A (ko) | 2014-08-20 |
| AU2019204591A1 (en) | 2019-07-18 |
| CN104039813A (zh) | 2014-09-10 |
| RU2635547C2 (ru) | 2017-11-14 |
| HK1202124A1 (zh) | 2015-09-18 |
| US20130123193A1 (en) | 2013-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2856034C (en) | Cyclosporin a form 2 and method of making same | |
| AU2020270500B2 (en) | Suspensions of cyclosporin A Form 2 | |
| HK1228924A (en) | A process for crystallization of cyclosporin a form 2 | |
| HK1228924A1 (en) | A process for crystallization of cyclosporin a form 2 | |
| HK1228924B (en) | A process for crystallization of cyclosporin a form 2 | |
| HK1202124B (en) | Cyclosporine a form 2 and method of making same | |
| HK1202066B (en) | Suspensions of cyclosporin a form 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140515 |